Q3 2025 Earnings Call Transcript November 6, 2025 AstraZeneca PLC beats earnings expectations. Reported EPS is $1.19, ...

AstraZeneca Pharma India reported a robust second quarter, with profit rising 41% year-on-year to ₹54.2 crore and revenue up 37%.

Acknowledging China’s innovative biotech environment, UK-headquartered pharmaceutical company AstraZeneca said it is confident about further investing in the country, and working with local ...

Drugmakers feel empowered to resist foreign price controls — confident that the Trump administration will have their backs.

(Reuters) -Several pharmaceutical companies have said they will sell drugs direct to patients in the U.S. and offered discounts following President Donald Trump’s calls to bring down drug prices and ...

AstraZeneca ( ($AZN) ) has released its Q3 earnings. Here is a breakdown of the information AstraZeneca presented to its investors. AstraZeneca is ...

AstraZeneca posted its third-quarter and nine-month figures well before market open that day. These revealed that the company ...

AstraZeneca chief exec Pascal Soriot (pictured) said Britain should be trying to attract cash from the pharmaceutical sector but was pushing it away.

Q3 2025 Earnings Call November 6, 2025 8:00 AM ESTCompany ParticipantsAndrew Barnett - Head of Investor RelationsPascal Soriot - ...

AstraZeneca PLC (AZN) reports an 11% revenue increase, driven by oncology and biopharmaceuticals, while navigating R&D ...

The highlight of AstraZeneca's latest results is the maintained full-year outlook despite the recent US drug pricing agreement. Click to read why AZN is a Hold.